Abstract
Over the last 70 years, pharmacotherapy in gout with urate-lowering drugs has consisted of four drugs only: In 1952, a mild uricosuric probenecid became available, the xanthine oxidase inhibitor Allopurinol in 1964, and the latter became the most frequently used urate-lowering drug worldwide; in the Eurozone, the uricosuric benzbromarone was welcomed in 1977. Only in 2002, the potent non-purine xanthine oxidase inhibitor febuxostat was introduced. In many countries, uricosurics such as probenecid and benzbromarone have not been available up to now, and these days, the new uricosuric lesinurad is the first uricosuric that may be introduced in these countries, which is the reason for describing the position this novel uricosuric deserves in treating gout. Recent literature will be shortly reviewed, and the current proposed position for lesinurad will be given as an aid for clinicians.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ragab G, Elshahaly M, Bardin T (2017) Gout: an old disease in new perspective. A review. J Adv Res 8:495–511
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2016) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2016-209707
Abhishek A, Doherty M (2018) Education and non-pharmacological approaches for gout. Rheumatology (Oxford) 57(suppl_1):i51–i58. https://doi.org/10.1093/rheumatology/kex421
Miner J, Tan Ph K, Hyndman D et al (2016) Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther 18:2014–2023
Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4: DOI https://doi.org/10.1002/hep/1840040223
Dua P, Gurrell R, Kirby S, Sudworth M, Loudon PT (2016) Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. Clin Rheumatol 35:2045–2051
Lee MH, Graham GG, Williams KM, Day RO (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was withdrawal from the market in the best interest of patients? Drug Saf 31:643–665
Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K (2017) Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extensions study. Rheumatology 56:2170–2178. https://doi.org/10.1093/rheumatology/kex350
Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F (2017) Lesinurad, a selective uric acid reabsorption inhibitor, in comparison with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheum 69:1903–1913
Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA (2017) Lesinurad combined with allopurinol: a randomized, double blind, placebo controlled study in gout patients with an inadequate response to standard-of-care allopurinol. Arthritis Rheum 69:203–212
Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A (2017) Lesinsurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard-of-care (the multinational CLEAR 2 study). Ann Rheum Dis 76:811–820
Bardin Th, Karra RG, So A, Tausche A-K, Wild I, Hagedorn H, Kandaswamy P, Perez-Ruiz F. (2018) Lesinurad adjunctive therapy with allopurinol in patients not responding to allopurinol monotherapy: pooled post-hoc safety and efficacy analysis in a patient subgroup using concomitant diuretics at baseline Ann Rheum Dis 77: DOI: https://doi.org/10.1136/annrheumdis-2018-eular.2812
Shen Z, Tieu K, Wilson D, Bucci G, Gillen M, Lee C, Kerr B (2017) Evaluation of pharmacokinetic interactions between Lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout. Clin Pharmacol in Drug Development 6(4):377–387. https://doi.org/10.1002/cpdd.323
Shen Z, Tieu K, Wilson D, Bucci G, Gillen M, Lee C, Keer B (2017) Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout treatment. Clin Pharmacol Drug Dev 6:377–387. https://doi.org/10.1002/cpdd.323
Van Booven D, Marsh S, McLeod H, Whirl Carrillod M, Sangkuhld K, Kleind TE, Altman RB (2010) Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 20(4):277–281. https://doi.org/10.1097/FPC.0b013e3283349e84
Reinders MK, Van Roon EN, Jansen TLTA et al (2009) Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68(1):51–56. https://doi.org/10.1136/ard.2007.083071
Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 68(6):892–897. https://doi.org/10.1136/ard.2008.091462
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
TJ: Research support from Ardea/Olatec; Lecture fees from Grunenthal; Consultancy fees from Abbvie/Astra-Zeneca/Celgene/Novartis; FPR: Consultancy fee for AstraZeneca, Horizon, Grünenthal, Menarini; speaker for Grünenthal and Menarini; investigation funds from Spanish Rheumatology Foundation and Cruces Hospital Rheumatology Association; A-KT: Research support from Ardea Biosience/Astra Zeneca, Berlin Chemie Menarini; Lecture fees from Berlin Chemie Menarini, Gruenenthal, Novartis; PR: fees from Ipsen, Menarini, Grünenthal, Savient.
Rights and permissions
About this article
Cite this article
Jansen, T.L., Perez-Ruiz, F., Tausche, AK. et al. International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol 37, 3159–3165 (2018). https://doi.org/10.1007/s10067-018-4306-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4306-9